Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting

Clin Lymphoma Myeloma Leuk. 2024 Mar 22:S2152-2650(24)00112-5. doi: 10.1016/j.clml.2024.03.005. Online ahead of print.ABSTRACTImmunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.PMID:38627181 | DOI:10.1016/j.clml.2024.03.005
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research